Symbols

ABVC

ABVC BioPharma·NASDAQ

--(--)

Signals Analysis

Bullish signal 0

Bearish signal 3

Significant Revenue Decline

Significant Net Income Decline

Low Cash Short-term Debt Ratio

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About ABVC

Abvc Biopharma, Inc.

A clinical-stage biopharmaceutical company that specializes in oncology, hematology, and ophthamology therapeutic areas

Industry

Pharmaceutical

Established Date

02/06/2002

Listing Date

08/03/2021

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.abvcpharma.com

Security Type

Common stock

Office address

44370 Old Warm Springs Blvd., Fremont, CA 94538

Business

Introduction

ABVC BioPharma, Inc., was incorporated under the laws of the State of Nevada on February 6, 2002. The Company is engaged in the biotechnology business through its operating entity, American BriVision Corporation (incorporated in Delaware in July 2015), focusing on unmet medical needs, with a focus on the development of new drugs and medical devices derived from plants. BriVision expands its product line by closely tracking new medical discoveries or medical device technologies from research institutions in the Asia Pacific region. The company carefully reviews preclinical studies, disease animal model studies, and phase I safety studies to screen out drugs that BriVision believes have efficacy and safety. Once a drug is deemed a suitable candidate for development and final commercialization, BriVision obtains a license for the drug or medical device from the original investigator and begins presenting the clinical protocol of the drug to respected principal investigators in the United States, Australia and Taiwan for Phase II clinical trials. Currently, clinical trials of the company's drugs and medical devices are being conducted at world-renowned institutions such as Stanford University, University of California, San Francisco (UCSF) and Cedarsene Medical Center (CSMC).

Company Financials

EPS

ABVC has released its 2025 Q2 earnings. EPS was reported at -0.13, versus the expected 0, missing expectations. The chart below visualizes how ABVC has performed over recent quarters, highlighting trends in earnings surprises.